The complaint, filed by the firm SueWallSt, targets Phreesia’s disclosures between May 8, 2025, and March 30, 2026. According to the filing, the company projected 14% to 16% revenue growth for fiscal 2027 while allegedly ignoring clear signs that pharmaceutical manufacturers were reducing their spending. The lawsuit contends that management repeatedly assured investors of predictable visibility into these commitments, even as client demand weakened due to regulatory shifts and brand-specific pressures.

When the company finally adjusted its outlook on March 30, 2026, the projected revenue midpoint dropped by approximately $37 million, leading to a $3.03 per share loss for investors. Attorney Joseph E. Levi argues that the case highlights fundamental questions regarding disclosure obligations when companies build forward guidance on softening client contracts. Shareholders who purchased Phreesia securities during the specified period and suffered financial losses have until July 13, 2026, to apply for lead plaintiff status.